Our Approach to Corporate Responsibility
At Ionis, we work with a sense of urgency to discover, develop and deliver medicines to create a better future for people with serious diseases. We believe operating responsibly and sustainably creates long-term value for our company and our stakeholders.
As our business grows, Ionis continues to reinforce our commitment to corporate responsibility in all aspects of our work. Our three corporate responsibility strategic pillars and associated goals guide our approach and provide a framework for reporting on our performance.
To learn more about our corporate responsibility priorities, download our Materiality Assessment.
Corporate Responsibility Report
To learn more about our corporate responsibility priorities, download our Corporate Responsibility Report.
Corporate Responsibility Strategic Pillars
We innovate across the business and work tirelessly to discover, develop and deliver important new medicines for people with serious diseases.
Goals
- Maintain strong investment in innovative R&D rooted in the needs of people with serious disease
- Collaborate with organizations that address important needs in patient communities
- Ensure high-quality processes to support clinical development and safe, reliable product supply
- Support equitable access and affordability of our medicines
We are committed to fostering an inclusive culture that drives excellence, embraces diversity and supports our communities.
Goals
- Cultivate a thriving workplace culture that is safe, inclusive and fosters innovation
- Continue to strengthen and expand diversity, equity and inclusion across the company
- Drive positive social impact through employee volunteerism and community support
We operate with integrity to help create a better, more sustainable future for all through environmental stewardship and responsible business practices and stakeholder interactions.
Goals
- Act with integrity and uphold our commitment to high ethical standards
- Responsibly manage our environmental impact as we grow our operations
Our 2024 Corporate Responsibility Report
Our 2024 Corporate Responsibility Report is our fourth annual report and details our ongoing commitment to corporate responsibility and transparency through enhanced disclosures. This report outlines our progress across our three CR pillars and associated goals that we introduced last year.
Report highlights include:
- Celebrated the U.S. approval of TRYNGOLZA™ (olezarsen) for adults with FCS as an adjunct to diet, our first independent medicine
- Introduced Ionis Every Step™, a comprehensive program for patients and healthcare providers, which includes affordability and access support
- Announced positive pivotal results for donidalorsen for hereditary angioedema (HAE), and continued to advance our clinical pipeline
- Partnered with more than 100 patient and caregiver community groups across the globe
- Continued to foster an inclusive workplace and recognize outstanding employees for their positive impact on Ionis’ culture and core principles
- Gave back to our local communities through 1,500+ hours of employee volunteering and $3.5M in corporate contributions
- Recognized as one of the Best Places to Work in 2024 by the San Diego Business Journal
- Prepared for our first independent commercial launch by updating policies, resources and training aligned with the PhRMA Code, such as guidelines for patient and HCP interactions and salesforce engagement
- Continued to sustainably manage our environmental impact with a 6% reduction in Scope 1 and 2 greenhouse gas emissions compared to 2023
